Koji Kato

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Hematology, Oncology +9

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Fowler, Michael Dickinson, Martin Dreyling et al. · Nature Medicine · 2021 · 527 citations · Full text

Medicine, Hematology, Oncology +12

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

Michael R. Bishop, Michael Dickinson, Duncan Purtill et al. · New England Journal of Medicine · 2021 · 520 citations · Full text

Medicine, Hematology, Oncology +9

The landscape of somatic mutations in Down syndrome–related myeloid disorders

Kenichi Yoshida, Tsutomu Toki, Yusuke Okuno et al. · Nature Genetics · 2013 · 387 citations

Life Sciences, Genetics, Molecular Genetics +15